ArticleEuropean geriatric medicine2022
Efficacy of COVID-19 vaccine booster doses in older people.
Article in European geriatric medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunobridging Study: Immunogenicity and Safety of Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) Vaccine as Heterologue Booster in Adult Subjects in Indonesia
Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia
Immunobridging Study: Immunogenicity and Safety of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) as Heterologue Booster in Adolescent Subjects in Indonesia
Who cites it
28 citing papers in PubMed.
- Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study.Frontiers in immunology · 2026Trial
- Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.The Journal of infectious diseases · 2023Trial
- Immunogenicity, security and protection against small ruminant lentivirus (SRLV) challenge in sheep, induced by intranasal immunization with a recombinant Sendai virus vector expressing SRLV gag-P25.The veterinary quarterly · 2025Article
- The associations between childhood vaccine history and COVID-19 vaccine uptake among older adults in 28 high-income countries.Research square · 2025Article
- Healthcare utilization among Japanese older adults during later stage of prolonged pandemic.Scientific reports · 2025Article
- Impact of vaccination and SARS-CoV-2 variants on severe COVID-19 outcomes: a cross-sectional study, Brazil, 2021-2022.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025Article
- Enhancing COVID-19 booster vaccination among the elderly through text message reminders.Human vaccines & immunotherapeutics · 2024Article
- Article
- Handgrip strength as a prognostic factor for COVID-19 mortality among older adult patients admitted to the intensive care unit (ICU): a comparison Alpha (B.1.1.7) and Delta (B.1.617.2) variants.Scientific reports · 2024Article
- Article
- Review
- Article
- Article
- Real-world effectiveness of mRNA COVID-19 vaccines in the elderly during the Delta and Omicron variants: Systematic review.World journal of meta-analysis · 2023Article
- The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence.Vaccines · 2023Review
- Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers.Clinical and experimental vaccine research · 2023Article
- Article
- Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers.Vaccines · 2023Article
- Article
- Clinical and epidemiological aspects of Delta and Gamma SARS-CoV-2 variant of concern from the western Brazilian Amazon.Memorias do Instituto Oswaldo Cruz · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe provide here an updated analysis on efficacy of COVID-19 vaccine booster doses in older people (i.e., aged ≥ 80 years) based on ongoing Italian nationwide COVID-19 vaccination campaign.
methodsData were obtained from the COVID-19 national integrated surveillance program, made available and regularly updated by the Italian National Institute of Health.
resultsCompared to those who completed the COVID-19 vaccination cycle for ≥ 5 months (n = 2,385,897), those receiving booster doses (n = 1,549,747) had 75% lower risk of SARS-CoV-2 infection, 82-83% lower risk of COVID-19 hospitalization and ICU admission, and 81% lower risk of death. Administration of COVID-19 vaccine boosters generated also greater protection (between 63 and 87% higher) against all these same endpoints compared to early completing (i.e., < 5 months; n = 335,458) a primary COVID-19 vaccination cycle.
conclusionsThe administration of COVID-19 vaccine booster doses is advisable for reducing the risk of morbidity and mortality in older people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.